The Motley Fool

3 Top Canadian Healthcare Stocks for Growth Investors

Image source: Getty Images

With an ageing population, a continent facing the possibility of recession, an industry making cutting-edge breakthroughs, one might think that an investment in health care is a no-brainer. Let’s take a look at three innovative stocks on the TSX that will give investors with a broad financial horizon a mix of defensive characteristics, capital gains, and dividends.


A biopharmaceutical company with a focus on clinical-stage cancer therapy and other immunotherapies, IMV (TSX:IMV)(NASDAQ:IMV) is committed to developing drugs that allow extended exposure of antigens to the human immune system. It’s one of the top pharma stocks on the TSX, and it’s trading near a 52-week low. While value investors may wish to wait for the knife to finish falling, there’s an opportunity to catch a tailwind should positive drug trial data materialize.

This stock has had a rough time of it lately but remains a solid play if you like beaten-up healthcare tickers. Snatching up shares in a stock that company insiders have been buying is almost always a smart play, as it indicates that there’s confidence in a price climb. With IMV’s position in the market lending a degree of defensiveness to your investment, you could be looking at a wide profit margin in a solidly recession-proof sector.

While it doesn’t pay a dividend, IMV stock has gained 200% in the last two years and could continue to grow as new immunotherapies are made more effective, more applicable, and more easily available to patients. Given that IMV’s patented system fills a key niche in modern medicine, there’s a lot of possibility for growth here.

5 TSX Stocks Under $5

Click here to learn more!


When it comes to overlooked healthcare stocks, personal mobility is an excellent investment idea if you’re looking for a recession-ready sector to harden up your dividend portfolio. Savaria (TSX:SIS) is the wide-moat option in this space and pays a decent dividend yield of 3.38% at today’s knocked-down price of $12.43. Revenue grew by 55% with adjusted EBITDA clearing 30% in a first quarter that should have growth investors salivating.

The stair-lift maker is active in a range of markets, manufacturing home elevators, wheelchair lifts, and other innovative adaptations for people with mobility challenges. The solutions available come under the trident of Accessibility, Adapted Vehicles, and Span. The latter segment covers therapeutics such as pressure management devices and support surfaces, while the adapted vehicles section covers van conversions.


Touted as a growth stock in the healthcare space, Vancouver-headquartered biotech company Zymeworks (TSX:ZYME)(NYSE:ZYME) rocketed on favourable clinical data this year. Growing 71.75% in the past year, Zymeworks is focused on innovative cancer treatments such as alternatives to hormone therapy and chemotherapy. When it held its IPO in May 2017, it was the largest domestic debut from a biotech company in over 10 years.

In other words, Zymeworks is a big deal and a solid buy for a healthcare investor looking for stocks with a lot of growth potential. An award-winning company in a niche sector, long-term investors seeking a canny capital gains play should consider stacking shares this cancer-focused biotech wunderkind.

The bottom line

With two cancer-treatment companies and a wide-moat mobility solutions business on the table, growth investors looking to make some smart money in a recession-hardy sector have some inviting options in this trio of stocks. Given their different approaches, both Zymeworks and IMV could be held without worrying too much about overexposure, while Savaria would make for a complementary passive-income investment.

5 Canadian Growth Stocks Under $5

We are giving away a FREE copy of our "5 Small-Cap Canadian Growth Stocks Under $5" report. These are 5 Canadian stocks that we think are screaming buys today.

Get Your Free Report Today

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Victoria Hetherington has no position in any of the stocks mentioned. Savaria is a recommendation of Hidden Gems Canada.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss an important event.

Iain Butler and the Stock Advisor Canada team only publish their new “buy alerts” twice a month, and only to an exclusively small group.

This is your chance to get in early on what could prove to be very special investment advice.

Enter your email address below to get started now, and join the other thousands of Canadians who have already signed up for their chance to get the market-beating advice from Stock Advisor Canada.